Leo Pharma invests $3.4M in melanoma app

Amsterdam-based dermatology app maker SkinVision has raised $3.4 million in funding from Leo Pharma, along with contributions from SkinVision’s existing investor and majority stakeholder, the Dutch investment firm Personal Health Solutions Capital.

SkinVision plans to extend the app’s functionality beyond analysis of photographs of users’ moles for melanoma detection, and into other skin conditions, while also expanding into additional geographical markets. SkinVision has a CE Mark in Europe but is not available in the US.

Leo Pharma senior vice president of global development, Kim Kjoeller, comments: “The internet is dramatically changing how consumers manage their health and that creates new opportunities for us to deliver innovative, value-added services.

Posted in Apps, Software Development, Technology, Validation